文献速递肿瘤 PET/CT核素与放射性配体治疗

177Lu-PSMA放射性配体治疗结束时PSMA PET/CT的预后价值:一项回顾性单中心分析

Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis.
PubMed 文献 · J Nucl Med · 2023-09-07

该单中心回顾性研究纳入20例接受177Lu-PSMA放射性配体治疗的转移性去势抵抗性前列腺癌患者,评估治疗结束时PSMA PET/CT的预后价值。结果显示,新发病灶、PSMA肿瘤体积进展和RECIP 1.0进展均与更短的总生存期相关,PSA进展亦与更短总生存期相关。作者认为需在更大规模的前瞻性多中心临床试验中验证。

要点

  • 治疗结束时PSMA PET/CT出现新发病灶者总生存期短于无新发病灶者(中位10.7个月 vs 未达到,P=0.002)。
  • PSMA肿瘤体积进展者总生存期短于非进展者(中位10.7个月 vs 未达到,P=0.007)。
  • RECIP 1.0进展者总生存期短于非进展者(中位10.7个月 vs 未达到,P=0.007)。

核心结论

  • 在这项20例接受PSMA-RLT的mCRPC患者回顾性研究中,治疗结束时PSMA PET/CT上新发病灶、PSMA肿瘤体积变化和RECIP 1.0定义的进展对总生存期具有预后价值。
  • 作者认为需要在更大规模的前瞻性多中心临床试验中验证。

研究设计与样本

  • 本研究为单中心回顾性研究。
  • 纳入接受PSMA-RLT且具备基线PSMA PET/CT(bPET)和治疗结束时PSMA PET/CT(ePET)的mCRPC患者,ePET需在末次PSMA-RLT周期后6个月内完成。
  • 共纳入20例mCRPC患者。
  • 中位治疗周期数为3.5(四分位距[IQR],2-4)。
  • bPET与PSMA-RLT第1周期之间的中位时间为1.0个月(IQR,0.7-1.8个月)。

主要发现

  • 20例患者中12例(60%)在末次随访时已死亡。
  • 存活者从ePET起的中位随访时间为31.2个月(IQR,6.8-40.7个月)。
  • 从ePET起的中位总生存期为11.4个月(IQR,6.8-30.7个月)。
  • ePET有新发病灶者总生存期短于无新发病灶者(中位总生存期10.7个月[95%CI,9.2-12.2] vs 未达到;P=0.002)。
  • PSMA肿瘤体积进展者总生存期短于非进展者(中位总生存期10.7个月[95%CI,9.7-11.7] vs 未达到;P=0.007)。

关键数值与推荐

  • PSMA-PET肿瘤分割用于获得全身PSMA肿瘤体积(PSMA-VOL),并定义进展(增加≥20%)与非进展性疾病。
  • bPET与ePET配对判读新发病灶。
  • 应用PSMA-PET/CT反应评价标准(RECIP)1.0定义进展与非进展性疾病。
  • ePET时PSA进展状态按前列腺癌临床试验工作组3(Prostate Cancer Clinical Trials Working Group 3)标准判定。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 本研究为回顾性研究。
  • 本研究为单中心研究。
  • 样本量为20例mCRPC患者。
  • 作者认为需要在更大规模的前瞻性多中心临床试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our objective was to evaluate the prognostic value of end-of-treatment prostate-specific membrane antigen (PSMA) PET/CT (PSMA-PET) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with 177Lu-PSMA radioligand therapy (PSMA-RLT). Methods: This was a single-center retrospective study. mCRPC patients who underwent PSMA-RLT with available baseline PSMA-PET (bPET) and end-of-treatment PSMA-PET (ePET) within 6 mo of the last PSMA-RLT cycle were eligible. Overall survival (OS) and prostate-specific antigen (PSA) progression status at the time of ePET (by Prostate Cancer Clinical Trials Working Group 3 criteria) were collected. PSMA-PET tumor segmentation was performed to obtain whole-body PSMA tumor volume (PSMA-VOL) and define progressive (≥20% increase) versus nonprogressive disease. Pairs of bPET and ePET were interpreted for appearance of new lesions. Response Evaluation Criteria in PSMA-PET/CT (RECIP) 1.0 were also applied to define progressive versus nonprogressive disease. The associations between changes in PSMA-VOL, new lesions, RECIP 1.0, and PSA progression status at the time of ePET with OS were evaluated by Kaplan-Meier analysis. Results: Twenty mCRPC patients were included. The median number of treatment cycles was 3.5 (interquartile range [IQR], 2-4). The median time between bPET and cycle 1 of PSMA-RLT was 1.0 mo (IQR, 0.7-1.8 mo). The median time between the last cycle of PSMA-RLT and ePET was 1.9 mo (IQR, 1.2-3.5 mo). Twelve of 20 patients (60%) had died at the last follow-up. The median follow-up time from ePET for survivors was 31.2 mo (IQR, 6.8-40.7 mo). The median OS from ePET was 11.4 mo (IQR, 6.8-30.7 mo). Patients with new lesions on ePET had shorter OS than those without new lesions (median OS, 10.7 mo [95% CI, 9.2-12.2] vs. not reached; P = 0.002). Patients with progressive PSMA-VOL had shorter OS than those with nonprogressive PSMA-VOL (median OS, 10.7 mo [95% CI: 9.7-11.7 mo] vs. not reached; P = 0.007). Patients with progressive RECIP had shorter OS than those with nonprogressive RECIP (median OS, 10.7 mo [95% CI, 9.7-11.7 mo] vs. not reached; P = 0.007). PSA progression at the time of ePET was associated with shorter OS (median, 10.9 mo [95% CI, 9.4-12.4 mo] vs. not reached; P = 0.028). Conclusion: In this retrospective study of 20 mCRPC patients treated with PSMA-RLT, progression on ePET by the appearance of new lesions, changes in PSMA-VOL, and RECIP 1.0 was prognostic for OS. Validation in larger, prospective multicentric clinical trials is warranted.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Murthy V, Gafita A, Thin P, et al. Prognostic Value of End-of-Treatment PSMA PET/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023. PMID: 37678927. doi:10.2967/jnumed.122.265155

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。